We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical and biotechnology companies, and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Recently disclosed research collaborations include those with Servier, Daiichi Sankyo, Lundbeck, PhoreMost, Taisho and Asahi Kasei Pharma, and we seek additional partnerships.
To find out more about partnering with us, please contact us.
We are involved in a number of research collaborations with major pharmaceutical and biotechnology companies, and academic partners. These range from early stage research, establishing target tractability, through to late-stage lead optimisation programs. We value close cooperation with our collaborators to ensure that the combined strengths of the partners are most effectively deployed to deliver drug candidates. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success.
Recently disclosed collaborations include those with:
Daiichi Sankyo: a research collaboration on undisclosed oncology targets.
PhoreMost: a research collaboration on an undisclosed novel oncology target.
For further information about collaboration opportunities, or to get more information about Vernalis Research capabilities, please feel free to contact us.
Drug discovery activities at Vernalis and with collaborators have generated pre-clinical candidates for many targets in various therapeutic areas.
|Vipadenant||Immuno-oncology||A2A||Redox Therapies (a BMS company)|
|AK179||Inflammation||IRAK4||Asahi Kasei Pharma|
|S55746||Oncology||Bcl-2||Servier in collaboration with Novartis|
|S65487||Oncology||Bcl-2||Servier in collaboration with Novartis|
|S64315||Oncology||Mcl-1||Servier in collaboration with Novartis|